Cash from Operations (Annual) Chart

Historical Cash from Operations (Annual) Data

View and export this data back to 1991. Start Trial.
Date Value
December 31, 2025 -268.58M
December 31, 2024 -500.95M
December 31, 2023 -307.51M
December 31, 2022 -274.37M
December 31, 2021 30.80M
December 31, 2020 35.89M
December 31, 2019 345.72M
December 31, 2018 602.89M
December 31, 2017 174.15M
December 31, 2016 -112.10M
December 31, 2015 21.12M
December 31, 2014 6.285M
December 31, 2013 63.49M
December 31, 2012 1.876M
December 31, 2011 -114.80M
December 31, 2010 -63.59M
December 31, 2009 -108.44M
December 31, 2008 212.03M
Date Value
December 31, 2007 36.09M
December 31, 2006 -53.22M
December 31, 2005 -61.74M
December 31, 2004 -101.75M
December 31, 2003 -95.47M
December 31, 2002 -94.38M
December 31, 2001 -6.158M
December 31, 2000 -23.19M
December 31, 1999 -48.36M
December 31, 1998 -34.72M
December 31, 1997 -20.55M
December 31, 1996 -21.15M
December 31, 1995 -15.08M
December 31, 1994 -15.23M
December 31, 1993 -15.30M
December 31, 1992 -19.37M
December 31, 1991 -1.489M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 524.08M
Biogen, Inc. 2.205B
Vertex Pharmaceuticals, Inc. 3.631B
BridgeBio Pharma, Inc. -445.91M
Arrowhead Pharmaceuticals, Inc. 179.55M